EZH2 and acute myeloid leukemia: The preclinical data provided a rationale for the further development of the promising chemo-free combination of DZNeP with Ven for the treatment of AML patients ineligible for intensive chemotherapy, particularly in certain subtypes of poor-risk patients with high EZH2 and/or low PIK3IP1.